Shopping Cart
- Remove All
- Your shopping cart is currently empty
Pack Size | Price | Availability | Quantity |
---|---|---|---|
100 μg | $418 | 7-10 days | |
500 μg | $1,670 | 7-10 days | |
1 mg | $2,800 | 7-10 days |
Biological Information | Activity has not been tested. It is theoretically active, but we cannot guarantee it. If you require protein activity, we recommend choosing the eukaryotic expression version first. |
Description | Glycophorin A Protein, Mouse, Recombinant (His) is expressed in HEK293 mammalian cells with C-His tag. The predicted molecular weight is 12.4 kDa and the accession number is P14220. |
Species | Mouse |
Expression System | HEK293 Cells |
Tag | C-His |
Accession Number | P14220 |
Synonyms | MNS,CD235a,HGpMiIII,MN,Glycophorin A,GpMiIII,GPSAT,PAS-2,HGpMiX,GPA,GYPA,Glycophorin-A,HGpMiV,HGpSta(C),HGpMiXI,GPErik |
Construction | Met1-Val108 |
Protein Purity | > 95% as determined by Tris-Bis PAGE |
Molecular Weight | 12.4 kDa (predicted). Due to glycosylation, the protein migrates to 47-55 kDa based on Tris-Bis PAGE result. |
Endotoxin | < 1 EU/μg by the LAL method. |
Formulation | Lyophilized from a solution filtered through a 0.22 μm filter, containing PBS (pH 7.4). Typically, 8% trehalose is incorporated as a protective agent before lyophilization. |
Reconstitution | Reconstitute the lyophilized protein in distilled water. The product concentration should not be less than 100 μg/ml. Before opening, centrifuge the tube to collect powder at the bottom. After adding the reconstitution buffer, avoid vortexing or pipetting for mixing. |
Stability & Storage | It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots. |
Shipping | In general, Lyophilized powders are shipping with blue ice. |
Research Background | Granulomatosis with polyangiitis (GPA) presents a wide spectrum of manifestations from the common respiratory symptoms to infrequent neurological and cardiac complications. The challenge in diagnosis and management makes the rapidly progressive disorder one of the most challenging dilemmas in clinical medicine.The ultimate goal is an improved prognosis through outcome measures which assesses the disease control with minimal adverse effects of intensive immunosuppressive regimens, an integral part of the clinical approach to improve the quality of life of GPA patients. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.